A phase Ⅲ, multi-center, randomized, double-blinded, active comparator, factorial design clinical trial to compare the efficacy and safety of a combination therapy of ezetimibe and rosuvastatin versus monotherapy of rosuvastatin in hypercholesterolemia patients
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary) ; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms I-ROSETTE
- Sponsors Ildong Pharmaceutical
- 02 Feb 2018 Results published in the Clinical Therapeutics
- 12 Mar 2017 Status changed from recruiting to completed.
- 27 Apr 2016 New trial record